Septerna’s lead program is in Phase 1 testing for hypoparathyroidism. The therapies available and in development for this rare disease are injectable, and Septerna aims to stand apart with an oral GPCR-targeting small molecule.
Ten months in, CEO of Arena Pharmaceuticals Amit Munshi has made some radical changes to the fragmented company, pulling away from its flagship weight loss drug to focus on the clinical pipeline.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.